Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

Delayed Quote. Delayed  - 05/25 09:59:59 pm
89.56 USD   +1.29%
04/27 VERTEX PHARMACE : reports 1Q loss
04/27 VERTEX PHARMACE : Reports First Quarter 2016 Financial Results
04/19 VERTEX PHARMACE : Enterome signs IBD therapy agreement with Vertex
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/19/2016 05/20/2016 05/23/2016 05/24/2016 05/25/2016 Date
81.01(c) 84.7(c) 84.42(c) 88.42(c) 89.56(c) Last
1 674 371 1 659 482 1 223 830 1 503 025 1 598 630 Volume
-0.86% +4.55% -0.33% +4.74% +1.29% Change
More quotes
Financials ($)
Sales 2016 1 783 M
EBIT 2016 280 M
Net income 2016 18,6 M
Finance 2016 414 M
Yield 2016 -
Sales 2017 2 574 M
EBIT 2017 898 M
Net income 2017 592 M
Finance 2017 1 437 M
Yield 2017 -
P/E ratio 2016 797,51
P/E ratio 2017 37,41
EV / Sales 2016 12,2x
EV / Sales 2017 8,05x
Capitalization 22 153 M
More Financials
Company
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets.It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS INC
04/28 VERTEX PHARMACEUTICALS : to Announce First Quarter 2016 Financial Results on Apr..
04/28 VERTEX PHARMACEUTICALS : Patent Issued for Solid Forms of 3-(6-(1-(2,2-Difluorob..
04/27 VERTEX PHARMACEUTICALS : reports 1Q loss
04/27 VERTEX PHARMACEUTICALS : Reports First Quarter 2016 Financial Results
04/21 VERTEX PHARMACEUTICALS : New Fenamates Study Findings Have Been Reported from Ve..
04/19 VERTEX PHARMACEUTICALS : Enterome signs IBD therapy agreement with Vertex
04/18 S&P 500 MOVERS : Chk, has
04/18 VERTEX PHARMACEUTICALS : Nivalis Therapeutics Appoints David Rodman, MD as Chief..
More news
Sector news : Bio Therapeutic Drugs
08:49aDJSANOFI : Moves to Replace Medivation's Board -- WSJ
06:16aDJREGENERON PHARMACEUTICALS : Named as Science Talent Search Sponsor
01:10a AMGEN : Announces Early Tender Results Of Senior Notes Exchange Offers
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/25 Best Performing Nasdaq 100 Stocks
05/23 Is It Time To Sell Gilead Sciences?
05/22 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2016 Update
05/11 CONCERT PHARMACEUTICALS : Investors Ignoring A New Blockbuster
05/07 CONCERT PHARMACEUTICALS : Jump Back Into Healthcare With This Specialty Pharma P..
Comments 
Advertisement
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions